Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

By In The News
January 31, 2019 in The Headlines

Recommended Posts

In The News

Posted January 31, 2019

- Share

Posted January 31, 2019

RARITAN, N.J., Jan. 31, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage gene therapy company, to develop, manufacture and...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  221112
2. Jaydee
  17346
3. deicer
  12756
4. Kip Powick
  12274
5. dagger
  9601
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  271.4k
- Total Posts
  
  562k

Sign In

Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support